Bryce Comstock

MCASOM 25, Moffitt Radonc Resident, Father, Husband. Tweets/Retweets are personal opinion, not that of my employer

[ASTRO @ASTRO_org]

ASTRO is pleased to announce the recipients of the 2026 Mentorship Award:
🎖️Beth Erickson, MD, FASTRO
🎖️Clifton (Dave) Fuller, MD, PhD, FASTRO
🎖️Meredith Giuliani, MBBS, MEd, PhD

Please join us in congratulating them before we celebrate their achievements during the Annual Meeting Awards Ceremony!

Learn more: https://t.co/k6VpyTmJbu

@BethEri81895034 @MeredithGiulia1

[UroToday.com @urotoday]

Real-world analysis of lutetium-177 in #mCRPC by taxane treatment sequence. @Micah_Ostrowski @UUtah joins @neerajaiims @huntsmancancer to discuss an analysis of 850 metastatic castration-resistant prostate cancer patients from Flatiron Health Research Database examining lutetium-177 PSMA-617 efficacy across three cohorts. #WatchNow > https://t.co/q4072wmfps

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Bladder preservation in muscle-invasive bladder cancer (MIBC) is evidence-based, patient-centered, and underutilized

The latest @IBCG_BladderCA consensus in @EUplatinum offers global expert recommendations on when, how, and for whom bladder-sparing strategies are appropriate 🧵1/5

#BladderCancer #AUA25 #OncSurgery #PatientCenteredCare @shilpaonc @achoud72 @FaltasLab @mouwlab @AndreaNecchi @PGrivasMDPhD @UrogerliMD @danielgrass

[MoffittRadOnc @MoffittRadOnc]

Congrats to our PGY-4 @celinachiodo !

[MoffittRadOnc @MoffittRadOnc]

Today we welcome our new PGY-2s!

[Bryce Comstock @bryce_comstock]

Would also like to add. Dr Paul Brown to this list. He is not a research mentor, but is a legend in the field. He is the most humble caring physician I have had the chance to be around, and always took his time to make me feel included and supported during my time at Mayo. He is who I plan to shape both my personal life and professional life like.

[Bryce Comstock @bryce_comstock]

Very excited to be starting my first day of Radonc! I can't thank my mentors enough for making this happen, Dr. Dawn Owen, Dr. Robert Mutter, Dr. Ryan Phillips, Dr. Krishan Jethwa, and most importantly Dr. Brian Davis. I am so excited to be working at Moffitt!

[Sushil @Sushilberiwal]

First randomised trial to show an overall survival benefit with MDT for oligomets in CRPC #pcsm

[Giulio Francolini @GiulioFrancoli1]

Excited to share the results of the #ARTO trial. After a median f-up of 53 months, Adding SBRT to abiraterone + ADT significantly improved overall survival (HR 0.55). @dicataldovanes1 @BarbaraJereczek @Ric_Campi @ChadTangMD @TheLancetOncol @ESTRO_RT
https://t.co/SpNaZHIByX

[Pietro Garlatti @PietroGarlatti]

Proud to share that ARTO trial long-term results are out in @TheLancetOncol! 📄✨
​In oligometCRPC, adding SBRT to abi+ADT significantly improves Overall Survival (HR 0.55, p=0.021). PFS 🎯 44 vs 17m!
@GiulioFrancoli1 @dicataldovanes1 @NiccolBertini2 @MicheleAquilano

[UroToday.com @urotoday]

Debating prostate radiotherapy for metastatic hormone-sensitive #ProstateCancer. @TylerSbrt7 @UCSanDiego joins @l_ballas @CedarsSinai outlining his approach to radiation therapy for the primary tumor in metastatic hormone-sensitive prostate cancer. He summarizes three randomized trials that consistently show a progression-free survival benefit, particularly in patients with low-volume metastatic disease. #WatchNow on UroToday > https://t.co/c4rtMC55Ng @APCCC_Lugano #APCCC26

[Giulia Marvaso @GiuliaMarvaso84]

🏆 Proud that our #RADIOSA post-hoc analysis was ranked among the top 5% of all abstracts submitted to #ESTRO2026. A great recognition for an incredible team effort. Thank you to all collaborators and patients who made this possible! #RadOnc #PCa #MDT

[Giulio Francolini @GiulioFrancoli1]

Thrilled to share that our abstract on the PERSIAN Trial (NCT03449719) was ranked among the Top 5% of all abstracts submitted to ESTRO 2026.
A fantastic recognition for the work of an exceptional team! #ESTRO2026 @dicataldovanes1 @PietroGarlatti

[Moffitt Cancer Center @MoffittNews]

https://t.co/5vCt3uJoEA

[Giulia Marvaso @GiuliaMarvaso84]

⚔️ SBRT first, systemic therapy always?
Great debate with @GiulioFrancoli1 on the management of oligomets PCa.
Different perspectives, same 🎯: not all pts are the same. Risk-adapted strategies should guide the integration of SBRT, ADT and ARPI, balancing disease control and QoL

[Chad Tang, MD @ChadTangMD]

Excited for the interest in our biomarker work from the urologic oncology community @VincentWenxinXu @PavlosMsaouel @AlexSherryMD @kieko_hara @d_shapiro1 @MDAndersonnews

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

Some doctors publish level 3-4 evidence, and the other doctors in their specialty celebrate it.

Radiation oncologists publish level 1-2 evidence, and other radiation oncologists criticize it.

[Moffitt Cancer Center @MoffittNews]

https://t.co/1dUNXVQMTI

[UroToday.com @urotoday]

Testosterone recovery dynamics after short-term ADT for localized #ProstateCancer. @BertrandTOMBAL @ClinUnivStLuc joins @neerajaiims @huntsmancancer outlines testosterone recovery dynamics after short-term ADT with radiation therapy. #WatchNow on UroToday > https://t.co/HrCjrN8l6a #APCCC26 @APCCC_Lugano

[Michael Hofman @DrMHofman]

Thrilled to share #PRIMARY2 Trial Results. This is the first randomised trial to show that adding [⁶⁸Ga]Ga-PSMA-11 PET-CT to MRI can safely halve the number of men needing a prostate biopsy.

Hot off the press in @TheLancetOncol 🎉

In 660 men across Australian sites with PI-RADS 2-3 but high clinical risk, PSMA-PET:
- Avoided biopsy in nearly half (49%)
- Was non-inferior for detecting clinically significant cancer (12% vs 16%)
- Halved the overdiagnosis of insignificant cancer (32% to 14%)

Fewer biopsies, less overdiagnosis, whilst not missing clinically significant prostate cancer: a real step forward for the diagnostic pathway.

Enormous congratulations to @ButeauJames @PeterMacCC , who led this as the centrepiece of his PhD and presented it as a plenary at #EAU26 in London. And to my brilliant co-lead @drlouiseemmett - this was a true partnership across our two centres.

Thank you to the UROLOGISTS @DrDanielMoon @declangmurphy (& many others), nuclear medicine physicians, technologists, radiopharmaceutical scientists across every site, and to @AnnetteVDHeyden and the @pros_tic who held it all together.

We are grateful to our funders: @PCF_Science, @nhmrc, St Vincent's Curran Foundation, Peter MacCallum Cancer Foundation, and @ANZUPtrials

Most of all, thank you to the 660 men who took part.

Open Access article: https://t.co/S0c60VLPBM